Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is conducting a study titled ‘An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria.’ The study aims to assess the long-term safety and effectiveness of the pozelimab and cemdisiran combination in treating paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. This research is significant as it explores potential new treatments for PNH, focusing on safety, efficacy, and the body’s response to the drugs.
The intervention involves two experimental drugs, pozelimab and cemdisiran, which are being tested for their ability to manage PNH symptoms and improve patient outcomes. These drugs are intended to work together to provide a more effective treatment option for those affected by PNH.
The study follows a non-randomized, parallel assignment model without masking, focusing on treatment as the primary purpose. This design allows researchers to observe the effects of the drug combination directly and assess its potential benefits and risks.
The study began on March 7, 2023, with an estimated primary completion date yet to be announced. The last update was submitted on August 18, 2025. These dates are crucial for tracking the study’s progress and anticipated milestones.
This clinical update could influence Regeneron’s stock performance and investor sentiment, as successful results may enhance the company’s market position in the pharmaceutical industry. Competitors in the PNH treatment space will be closely watching these developments, as they could shift market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.